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Complementary DNA portions coding for each domain (domain L and internally repetitive domains, do- 
mains 14, each composed of approximately 140 amino acid residues) of pig calpastatin were subcloned 
into E. coli plasmids to express the respective portions of the proteinase inhibitor gene in bacteria. Cell ex- 
tracts of E. coli harboring recombinant plasmids were assayed for calpain inhibition. All four internally 
repetitive domains howed inhibitory activities, essentially similar to one another, against calpains I and 
II. No inhibition was observed in the case of the N-terminal non-homologous domain (domain L). These 
results upport our previous conclusion that the repetitive region is a functional unit of the proteinase inhibi- 
tor. 
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1. INTRODUCTION 
Calpastatin is an endogenous inhibitor protein 
acting specifically on calpain (EC 3.4.22.17; 
Ca2+-dependent cysteine proteinase) (review [1]). 
Both calpain and calpastatin are known to be wide- 
ly distributed in mammalian and avian cells [2,3]. 
Although physiological roles of calpain have not 
yet been clarified, the proteinase-proteinase in- 
hibitor system has been suggested to play impor- 
tant roles in various cellular functions coupled 
with calcium ion mobilization [4-8]. 
Recently we determined a primary structure of 
pig calpastatin by nucleotide sequencing of cloned 
cDNAs and by the Edman degradation of the 
purified inhibitor from pig heart muscle [9]. As 
will be published elsewhere (Takano, E. et al., in 
preparation), the inhibitor protein is composed of 
713 amino acid residues, and contains four inter- 
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nally repetitive sequences (domains 1, 2, 3 and 4) 
and one non-homologous sequence on the N- 
terminal side (domain L), each being separated by 
intervals of approx. 140 amino acid residues. This 
structural feature is similar to the recently publish- 
ed structure of rabbit calpastatin [10]. 
Previously we demonstrated that one such 
repetitive region (domain 3) had calpain-specific 
inhibitory activity, and concluded that the struc- 
tural domain also represents a functional unit of 
calpastatin [11]. In the present study, we further 
subcloned cDNA portions for all the domains of 
pig calpastatin and compared their inhibitory ac- 
tivities against calpains I and II. 
2. MATERIALS AND METHODS 
2.1. Materials 
Most restriction endonucleases and other en- 
zymes for molecular biology were obtained from 
Takara Shuzo Co. (Kyoto, Japan). Plasmids 
pUCl l8  and pUCl l9  [12], and a dideox- 
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ynucleotide sequencing kit were from the same 
company. SaclI and NheI were from Toyobo 
(Osaka, Japan) and Nippon Gene (Toyama, 
Japan), respectively. Other reagent-grade 
chemicals were obtained from Wako Pure 
Chemicals (Osaka, Japan) or Nakarai Chemicals 
(Kyoto, Japan). 
2.2. Preparation of synthetic oligonucleotides 
Oligodeoxyribonucleotides for in vitro muta- 
genesis primers were synthesized by the 
phosphoramidite method [13] with an automatic 
DNA synthesizer (Applied Biosystems, model 
380B). After the synthesis, oligonucleotides were 
purified by high-performance liquid chroma- 
tography under the conditions recommended by 
Applied Biosystems and phosphorylated by T4 
polynucleotide kinase as described [14]. 
2.3. Site-directed mutagenesis 
Oligonucleotide-directed in vitro mutagenesis 
[15] was performed using a mutagenesis kit sup- 
plied by Amersham (Amersham, England) ac- 
cording to the provided protocol except-employing 
single-stranded DNAs of pUC118/119 derivatives 
as templates and reducing the reaction volume to 
a half of the original volume. Single-stranded 
DNAs were produced by infecting transformants 
of either E. coli.MV1304 or MVl184 harboring 
pUC118/119 derivatives with helper phage 
MI3K07 as described by Vieira and Messing [12]. 
After polyethyleneglycol precipitation [16], phage 
particles obtained from a 2-ml culture were treated 
with 0.1 ml of 50/zg/ml DNase I and 5/zg/ml 
RNase A in 10 mM Tris-HCl, pH 7.4, containing 
5 mM MgCI2 at 37°C for 30 min to digest con- 
taminating DNA and RNA derived from host ceils. 
After the addition of 20/A DNase stop solution 
(50 mM EDTA in 1.5 M sodium acetate, pH 7), 
single-stranded DNAs were extracted with phenol, 
and subsequently with chloroform as described 
[161. 
Filtration of dCTPcrS incorporated DNA 
through nitrocellulose filters was performed with a 
microfiltration unit S&S009 (Schleicher & Schuell, 
Dassel, FRG). After exonuclease III digestion, 
repair synthesis was primed with 5'-phos- 
phorylated synthetic oligonucleotide cor- 
responding to an MI3/pUC reverse primer 
(5' -TGTGGAATTGTGAGCGG-3 ' ). Mutants 
were screened by restriction analysis of isolated 
plasmids from transformants of E. coli MV1304 or 
MV1184. Mutation was confirmed by nucleotide 
sequencing. 
2.4. Subcloning of calpastatin cDNA fragment 
Restriction fragments of calpastatin cDNAs 
were inserted into multiple cloning sites of 
pUCll8, pUCll9 or pUCll8N, using T4 DNA 
ligase. A SaclI/EcoRI fragment from pPECS14 
and a 2-kb PstI fragment from pOBCSI was blunt- 
ended with T4 DNA polymerase as described [17] 
before ligation to the HinclI site of pUC119 and 
the SmaI site of pUCll8, respectively. A 
KpnI/Eco47III fragment from pPECS146NK was 
inserted into pUCll8N at KpnI/BamHI sites 
where the BamHI cleaved end was filled with a 
Klenow fragment of E. coli DNA polymerase as 
described [14]. A 16-mer synthetic double-stranded 
oligonucleotide of a universal translation ter- 
minator (5'-GCTTAATTAATTAAGC-3', Phar- 
macia, Uppsala, Sweden) was inserted to the 
HinclI site of pUCll8N derivatives to obtain 
clones pCSL and pCSD1. 
2.5. Caipain inhibition assay of E. coli cell 
extracts 
A preparation of cell extracts of E. coli 
545~-HR1 transformants was performed as 
described [11]. Addition of cAMP and isopropyl- 
~'-D-thiogalactoside (IPTG) to a culture medium 
was omitted in the present study. These inducers 
had little effect on the level increase of calpastatin 
activities in E. coli 545~-HR1 transformants. 
Protein concentration was determined by the 
method of Lowry et al. [18] using bovine serum 
albumin as a standard protein. Calpastatin activity 
was measured by the method of Murakami et al. 
[19] using low- (or/~M) Ca2÷-requiring calpain I
purified from pig erythrocytes or high- (or mM) 
Ca2+-requiring calpain II purified from pig 
kidneys [20]. 
3. RESULTS 
Fig. 1 illustrates the scheme for the construction 
of recombinant plasmids which expressed each do- 
main of calpastatin i  E. coli. Calpastatin cDNA 
clones pOBCS1 [9] and pPECS14 [Takano et al. 
(1987), see above] were isolated and used for fur- 
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Fig. 1. Scheme for the construction of  plasmids which express calpastatin domains in E. coil Closed boxes and open 
boxes indicate translated and untranslated regions of  calpastatin cDNAs.  Abbreviations are used for restriction 
endonuclease cleavage sites: E, Eco47III; H, HindlII; K, KpnI; N, NcoI; Nh, NheI; P, PstI; R, EcoRI; S, SaclI; V, 
EcoRV. Restriction sites on vector DNAs are shown only for EcoRI, HindlII and NcoI. PstI sites on vector DNAs are 
not shown except the sites of  the dG-dC tail on the cDNAs.  
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ther subcloning. Restriction endonuclease cleavage 
sites of NcoI, KpnI and HindIII  were created in 
calpastatin cDNAs by in vitro site-directed 
mutagenesis as described in section 2. This techni- 
que was also employed to obtain plasmids 
pUC118N and pUC119N by creation of a NcoI site 
surrounding the translation initiation methionine 
codon of lacZ' of pUC118 and pUC119 (fig.2). 
The distance between the ribosome binding site 
and the initiation codon was also changed from 7 
to 8 nucleotide residues. This structure is similar to 
that of an efficient expression vector pKK233-2 
constructed by Amann and Brosius [21]. 
Appropriate restriction DNA fragments which 
contained each domain were subcloned into multi- 
ple cloning sites of pUC118, pUC119 or pUC118N 
(figs 1 and 2). Construction of pCSD3 was de- 
scribed in I l l ] .  Translation termination codons 
were introduced by a 16-mer double-stranded 
oligonucleotide of a universal translation ter- 
minator (pCSL and pCSD1), by in vitro site- 
directed mutagenesis (pCSD2) or by frameshift in- 
sertion at the PstI site which precedes a stop codon 
(TAG) in the XbaI site (pCSD3). The translation 
termination codon of pCSD4 is derived from the 
calpastatin cDNA. Thus the calpastatin segments 
expressed in E. coli contained non-calpastatin 
amino acid residues at N-termini (pCSD1, pCSD2, 
pCSD3 and pCSD4) or at C-termini (pCSL, 
pCSD1 and pCSD3). 
Crude cell extracts of E. coli transformants were 
tested for calpain inhibition (fig.3). Both calpains 
I and II were inhibited in a dose-dependent manner 
by the extracts from E. coli cells harboring pCSD 1, 
pCSD2, pCSD3 and pCSD4. No inhibition was 
observed in the case of pCSL under the conditions 
used. Since only crude E. coli cell extracts were 
used, the comparison of the inhibitory activities 
among the four domains (Panels C -F )  may not be 
quantitative. However, assuming the efficiency of 
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Fig.2. Nucleotide and amino acid sequences around N-termini and C-termini of calpastatin domains which are expressed 
in E. coli. Non-calpastatin residues are italicized. Substituted nucleotides by in vitro mutagenesis are underlined. 
Numbers below the amino acid residues indicate the residue number of pig calpastatin. Ribosome binding sites (RBS) 
of lacZ' genes of pUC118/119 and of pUC118N/119N are boxed. Asterisks indicate translation termination codons. 
Recognition sequences of major restriction endonucleases and universal translation terminators (16-mer) inserted at the 
HincII sites are indicated by solid lines above the nucleotide sequences. 
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Fig.3. Inhibition profiles of calpains I and II. Proteolytic activities of calpain I (e) and calpain II (A) were assayed in 
the presence of various amounts of crude cell extracts of E. coli harboring recombinant plasmids which expressed each 
domain of calpastatin: (A) pUC119, negative control; (B) pCSL, domain L; (C) pCSDI, domain 1; (D) pCSD2, domain 
2; (E) pCSD3, domain 3; (F) pCSD4, domain 4. 
the synthesis of proteins which includes the expres- 
sion of these calpastatin segments in E. coli har- 
boring different plasmids to be comparable, the 
four products eem to have similar specific activi- 
ty. With all the four domain proteins, the inhibi- 
tion of calpain I is weaker than that of calpain II, 
which is in agreement with what was previously 
reported in the case of intact calpastatin molecules 
[41. 
4. DISCUSSION 
Previously we claimed that the repetitive region 
of pig calpastatin is the functional unit of the pro- 
teinase inhibitor by demonstrating the production 
in E. coli of an active calpastatin segment which is 
composed of only one repetitive region (then 
designated as region Y, corresponding to domain 3 
in the present report) [11]. The present study has 
now clarified that all of the four repetitive regions 
(domains 1-4), but not the non-homologous 
region (domain L), possess the capability of in- 
hibiting calpains (fig.3). Domains 1-4 showed in- 
hibitory activities essentially similar to one 
another, suggesting that these are almost 
equivalent functional units of a calpastatin 
molecule. This agrees with previous stoichio- 
metrical observations that calpastatins have 
multiple binding sites for calpains [22]. Although 
stoichiometrical analysis of calpain binding to 
purified calpastatin segments still has to be carried 
out, each homologous domain is likely to bind to 
one calpain molecule. Imajoh et al. [23] reported 
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that the E. coli-expressed, truncated rabbit 
calpastatin, which contained two internally 
repetitive domains, inhibited 2 mol calpains. 
The multiple and internally repetitive sub- 
structure of a proteinase inhibitor is not unique to 
calpastatin. Kininogens contain three cystatin-like 
sequences in the N-terminal sides of the molecules 
(heavy chains) [24]. By stoichiometrical nalysis, 
Higashiyama et al. [25] showed two binding sites 
for papain per one molecule of human high- 
molecular-mass kininogen as well as of human 
low-molecular-mass kininogen. Using purified 
proteolytic fragments of human low-molecular- 
mass kininogen, Salvesen et al. [24] showed that 
two of the three repetitive segments have inhibitory 
activities against papain and cathepsin L. It is 
postulated that one of the repetitive domains lost 
its inhibitory function during evolution [26]. In 
contrast, all four repetitive domains of calpastatin 
maintain their inhibitory functions as de- 
monstrated in the present study. 
Although multiplication of a unit inhibitor do- 
main in calpastatin during evolution must have 
contributed to the increase of inhibitory capacities 
per one molecule of protein (4-fold, if disregarding 
any steric effect), biological significance of this 
multidomain structure remains to be solved. It is 
interesting to note that erythrocyte calpastatin may 
contain only three repetitive domains [Takano et 
al. (1987), see above]. Yamato et al. [27] reported 
the change of molecular size of calpastatin (from 
280 kDa to 34 kDa, estimated by gel filtration 
under non-denaturing conditions) in rat liver after 
the administration of phenylhydrazine. It is not 
known whether such smaller molecules are formed 
at the transcriptional or post-transcriptional stage 
of the biosynthesis of the calpastatin protein. More 
detailed structure-function relationship studies are 
required with various molecular forms of 
calpastatin. 
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